Company Sets New Quarterly Record for Number of Individual E-Commerce Order Transactions
New York, NY, March 25, 2022 (GLOBE NEWSWIRE) — via NewMediaWire —Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences and Pharmaceutical Development Company, today announced that it has received its 10,000thE-Commerce order. The Company has also set a new Quarterly record for “number of individual E-Commerce transactions.” Driving the strong performance in the Company’s E-Commerce business (its highest margin segment), are the following factors: increasing number of orders from repeat customers, expansion of product offerings, influencer-based marketing initiatives, and higher conversion rates (with respect to visitors to E-Commerce website).
E-Commerce Website: www.taurigum.com
In other news, the Company is pleased about the recently announced progress, pertaining to potential Federal Legalization Legislation. On March 24, 2022, the U.S. House of Representatives officially scheduled a Floor Vote for “Federal Marijuana Legalization Bill.” This Vote is expected to take place next week (March 28th– April 1st, 2022).
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum(TM), consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum(TM) Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum(TM) Flavors: Peach-Lemon, Black Currant), (DELTA 8 THC Infused Tauri-Gum(TM) Flavor: Evergreen Mint), (Vitamin C + Zinc Infused Tauri-Gum(TM) Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum(TM) Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum(TM) Flavor: Golden Raspberry). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum(TM), for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company’s clinical development efforts.
The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.
DISCLAIMER — Forward-Looking Statements
This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.
Contact:
Tauriga Sciences, Inc.
4 Nancy Court, Suite 4
Wappingers Falls, NY 12590
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Company Instagram: @taurigum
Personal Instagram: @sethsms47
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Project AED365 Aims to Empower Communities, Youth Organizations, First Responders, and more by Providing Lifesaving Automated…
The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages…
This heartfelt donation demonstrates Blazesoft's commitment to corporate social responsibility with a generous gift to…
GOLETA, Calif.--(BUSINESS WIRE)--$INGN #AirwayClearance--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products…
- Revenue grew to $1,078,090, an increase of over $1million year-over-yearDallas, Georgia--(Newsfile Corp. - December…
Epic, Oracle Health, MEDITECH and Altera Digital Health are redefining healthcare IT worldwide, as highlighted…